Bicycle Therapeutics plc BCYC

Updated: 9 Aug 2026

NASDAQ | Biotech | Biotechnology and oncology

No signal published yet

We already track Bicycle Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow Bicycle Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biotechnology and oncology
We're already tracking Bicycle Therapeutics plc — here are the latest events we've registered

Recent News

  • On July 30, 2026, Bicycle Therapeutics reported its second quarter 2026 financial results, ending the period with $510.1 million in cash and cash equivalents. The company highlighted ongoing clinical progress across its Bicycle conjugate and radiopharmaceutical pipeline, maintaining a cash runway projected into 2030.

What Firelda Watch includes for Bicycle Therapeutics plc

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Bicycle Therapeutics plc will be delivered in the same format.

Want to follow Bicycle Therapeutics plc? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow Bicycle Therapeutics free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Bicycle Therapeutics plc BCYC
Bicycle Therapeutics — follow and we'll monitor it
Follow Bicycle Therapeutics free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.